Cargando…
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475096/ https://www.ncbi.nlm.nih.gov/pubmed/31118715 http://dx.doi.org/10.2147/DMSO.S174568 |